Study

A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia

Study ID Alternative Stable ID Type
EGAS00001001150 Other

Study Description

Chronic myeloid leukaemia (CML) is characterised by the presence of a fusion driver oncogene, BCR-ABL1, which is a constitutive tyrosine kinase. Tyrosine kinase inhibitors (TKIs) are the central treatment strategy for CML patients and have significantly improved survival rates, but the T315I mutation in the kinase domain of BCR-ABL1 confers resistance to all clinically approved TKIs, except ponatinib. However, compound mutations can mediate resistance even to ponatinib and remain a clinical challenge in CML therapy. Here, we investigated a ponatinib-resistant CML patient through whole genome sequencing (WGS) to identify the cause of resistance and to find alternative therapeutic targets.

Study Datasets 4 datasets.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001001257
NA
Illumina HiSeq 2000 3
EGAD00001001258
NA
Illumina HiSeq 2000 5
EGAD00001001259
NA
Illumina HiSeq 2000 2
EGAD00001001260
NA
Illumina HiSeq 2000 2

Who archives the data?

Publications

Citations

Retrieving...
Retrieving...